Adarza BioSystems Closes Final Tranche $6.8M Series A Financing

Adarza BioSystems, Inc., a and St. Louis, Missouri- and Rochester, NY-based developer of label-free, multiplex assays, closed the final tranche of its $6.8m Series A financing.

Backers included Cultivation Capital Life Science Fund and Siemens Venture Capital.

The company intends to use the funds to launch its first 100-plex immunoassay product consumable and instrument product and accelerate development of assays targeting a variety of biological analytes.

Led by Rand Henke, Ph.D., Chief Executive Officer, Adarza develops and manufactures label-free biosensor assays and instruments servicing life science research, drug development and in vitro diagnostics customers. Its proprietary Arrayed Imaging ReflectometryTM detection platform is capable of identifying and quantifying a series of biological target analyte species in a fluid sample, without chemical labels or complex processing.



Join the discussion